Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Free Cash Flow for 6 consecutive years, with -$32.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 3.9% to -$32.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$135.3 million, a 18.04% decrease, with the full-year FY2025 number at -$135.3 million, down 18.04% from a year prior.
  • Free Cash Flow was -$32.0 million for Q4 2025 at TScan Therapeutics, down from -$29.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $8.9 million in Q3 2023 to a low of -$37.9 million in Q1 2025.
  • A 5-year average of -$22.0 million and a median of -$23.4 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 158.96% in 2023, then plummeted 400.39% in 2024.
  • TScan Therapeutics' Free Cash Flow stood at -$16.6 million in 2021, then increased by 4.27% to -$15.9 million in 2022, then tumbled by 67.29% to -$26.6 million in 2023, then fell by 15.76% to -$30.8 million in 2024, then fell by 3.9% to -$32.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Free Cash Flow are -$32.0 million (Q4 2025), -$29.7 million (Q3 2025), and -$35.7 million (Q2 2025).